CT Financial Advisors’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

CT Financial Advisors’s Portfolio MRTX Stock Details MRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	$1.04K	Hold	200	–	–	﹤0.01%	583
2016 Q4	$950	Hold	200	–	–	﹤0.01%	584
2016 Q3	$1.32K	Hold	200	–	–	﹤0.01%	571
2016 Q2	$1.09K	Hold	200	–	–	﹤0.01%	579
2016 Q1	$4.28K	Hold	200	–	–	﹤0.01%	519
2015 Q4	$6.32K	Hold	200	–	–	﹤0.01%	496
2015 Q3	$6.88K	Hold	200	–	–	﹤0.01%	499
2015 Q2	$6.29K	Buy	+200	New	+$5.89K	﹤0.01%	508

Other funds holding MRTX

Aviva Holdings New Providence, Bahamas $20.5M AUM 117.01% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

HIM

Hillhouse Investment Management Grand Cayman, Cayman Islands $3.13B AUM 7.29% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

CT Financial Advisors's MRTX Position: Q1 2017 in Review

CT Financial Advisors held its Mirati Therapeutics, Inc. Common Stock (MRTX) position steady in Q1 2017 at 200 shares worth $1.04K. The position accounts for ﹤0.01% of the portfolio, ranked #583.

CT Financial Advisors first reported a position in MRTX in Q2 2015 and has held it in 8 quarters since. The position peaked at $6.88K in Q3 2015. 64 funds tracked by Wall St. Rank hold MRTX as of Q1 2017.

CT Financial Advisors held 200 shares of Mirati Therapeutics, Inc. Common Stock worth $1.04K as of Q1 2017.
CT Financial Advisors left its Mirati Therapeutics, Inc. Common Stock share count unchanged in Q1 2017.
Mirati Therapeutics, Inc. Common Stock made up ﹤0.01% of CT Financial Advisors's portfolio in Q1 2017, its #583 holding.
CT Financial Advisors first reported a position in Mirati Therapeutics, Inc. Common Stock in Q2 2015 and has held it in 8 quarters since.
CT Financial Advisors's Mirati Therapeutics, Inc. Common Stock position peaked at $6.88K in Q3 2015.
64 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q1 2017.

Based on CT Financial Advisors's 13F filing for Q1 2017, filed 7 Apr 2017.